German chemicals giant BASF has approached smaller rival Evonik regarding a potential voluntary public takeover offer for all shares. The exploratory talks value Evonik at roughly 12 billion euros, sparking a sharp surge in share prices as Europe’s fragmented chemical sector faces mounting consolidation pressure.
Europe’s heavy industrial landscape is shifting beneath the weight of high energy costs, weak demand, and fierce global competition, and the pressure has just triggered a massive domestic move. Germany’s specialty chemicals group Evonik confirmed on Friday that Ludwigshafen-headquartered rival BASF made a non-binding approach concerning a voluntary public takeover of all shares in the Essen-based company.
The proposal immediately galvanized markets. Evonik shares surged up to 10.6 per cent, closing 7.2 per cent higher on Friday, while BASF stock pulled back between 2.7 and 3.6 per cent in Friday afternoon trading. The buyout discussions, first reported by trade publication Dealreporter on Tuesday, with the Financial Times also reporting on the potential deal on Friday, place Evonik’s enterprise value including net debt at approximately 12 billion euros, with a market capitalisation sitting around 8.4 billion euros to 9.2 billion euros.
Strategic Rationale and Market Pressures Behind the BASF-Evonik Approach
The proposed tie-up addresses severe structural headwinds confronting European producers. BASF is in advanced talks with Evonik and RAG-Stiftung about a potential merger, valuing Evonik at an enterprise value of about 12 billion euros. A deal would strengthen BASF’s product and geographic mix while creating a larger Germany-based player better positioned against Chinese and U.S. competitors. Trade publication Dealreporter also wrote this week that BASF had explored a possible merger with Evonik this year, and the Ludwigshafen-based group has also been speaking with banks about a potential deal since earlier this year and continues to work on the proposal, although the talks may still fail to produce an agreement.
A takeover would mark a major step by BASF chief executive Markus Kamieth to consolidate Europe’s fragmented chemicals industry, which is under pressure from weak demand, global overcapacity and higher input costs. For BASF, active consolidation would be a logical response to the structural weaknesses of the European market, said Linus Vogel of Deka Investment, a top-20 investor in both companies, pointing out that Evonik’s comparatively low valuation makes it an attractive potential partner.
Arne Rautenberg, head of equities at mutual-funds firm Union Investment, echoed that sentiment, noting that by acquiring Evonik, BASF could strengthen its position in the speciality chemicals sector and increase capacity utilisation.
Product Portfolios, Geographic Overlap, and the RAG-Stiftung Factor
Combining the two firms would create a combined BASF-Evonik entity with 74 billion euros in annual revenue and could achieve significant synergies, though regulatory scrutiny is expected amid a more supportive Brussels policy stance. Their product lines offer clear complementarities across industrial and specialty sectors. Evonik’s products include high-tech plastics, feed additives as well as ingredients for coatings and household products, while BASF makes engineering plastics, super absorbent polymers, vitamins and a wide range of chemicals for industrial uses.
Geographically, however, the companies are less complementary. Europe is the largest market for both and BASF has pledged to increase revenue contributions from Asia and other regions. Any deal requires managing complex stakeholder interests. The RAG Foundation, which holds 43 to 44 per cent in Evonik, also said it has been contacted by BASF regarding a takeover offer for Evonik, and the stance of RAG-Stiftung is likely to be decisive in whether a deal can proceed. People familiar with the business say Evonik’s shareholders and executives would need to be convinced that a combination with BASF offers a strong strategic fit as well as acceptable terms, and BASF has a market capitalisation of €45.8 billion ($52.2 billion), while Evonik is currently valued at €9.2 billion.
Current Deal Status and Regulatory Hurdles Ahead
Despite the high stakes, a completed transaction is far from guaranteed. Evonik said earlier it had received a non-binding approach from BASF regarding a voluntary public takeover offer for all shares of the company, but added no talks were currently taking place. BASF in a statement said it continuously evaluated the strategic option of acquisitions that strengthen its core businesses, deliver a strong strategic fit, drive profitable growth and create value and was in exploratory talks, adding that the outcome of the exploratory talks was open at this stage.
BASF, Evonik and RAG-Stiftung declined to comment. Whether these exploratory contacts translate into a formal merger proposal will depend heavily on valuation premiums, market conditions, and the ultimate decision of the RAG-Stiftung.